Diabetes, Growth Disorders Drive Sales of Pediatric Hormone Drugs

Thursday, February 7, 2008 General News J E 4
NEW YORK, Feb. 6 Prescription pediatric drugs represent anenormous market, with manufacturer sales totaling $36.9 billion in 2006.Though overall annual growth is forecast at a modest 3.2%, reaching $43billion by 2011, the hormone drug segment, with a market share of 11.7%, isexpected to achieve the highest growth rate of 8.3% during the same timeperiod, according to Kalorama Information's new report The World Market forPediatric Drugs.

The high growth rate of the prescription hormone drug segment in thepediatric population, both domestic and worldwide, can be attributed to anincrease in the incidence of diabetes, thyroid conditions, and growthdisorders, as well as improved screening procedures, better products,availability, effectiveness, education and delivery techniques suitable forchildren. Within the hormone segment, the highest growth rates are forantidiabetic agents and growth hormone drugs, at 9.1% and 14.4% respectivelyfrom 2004 to 2006 and estimated at 5.4% and 10.8% between 2006 and 2011.

"While the focus of most healthcare watchers has been the aging of theworld population, one must not forget that children number nearly 2.5 billion,or 40% of the humans on the planet," according to Bruce Carlson, publisher ofKalorama Information. "Developers are starting to see that there is a largeunmet need in pediatrics, especially in the hormone category."

Kalorama Information's report The World Market for Pediatric Drugs coversanti-infectives, cancer therapies, and drugs for allergy, respiratory,cardiovascular, central nervous system, gastrointestinal and hormonetreatments. Each segment details products, market estimates, forecasts through2011 and competitive analyses of leading providers. Extensive tables ofproducts in research and development and in-depth discussions of current andfuture issues and trends are also included, with additional insight from morethan 100 interviews with key industry experts. The report can be purchaseddirectly from Kalorama Information by visiting

About Kalorama Information

Kalorama Information supplies the latest in independent market research inthe life sciences, as well as a full range of custom research services. Formore information, contact Tom Ehart at 240-747-3014, or visit

SOURCE Kalorama Information


You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
Customer Experience Conference, Feb. 25-27: Sharin...
Philip Coelho Joins Mediware Board